ReviewFrontiers in immunology2019
The Regulatory Effects of Interleukin-4 Receptor Signaling on Neutrophils in Type 2 Immune Responses.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 85 citations in OpenAlex.
- Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment.The Journal of allergy and clinical immunology · 2023Trial
- A workflow to reduce red blood cell autofluorescence for imaging IL-4/IL-4R interactions in the inflamed lung.Biochemistry and biophysics reports · 2026Article
- Blood DNA methylation profile is altered in severe bronchiectasis.ERJ open research · 2026Article
- Extracellular Vesicle-Associated IL4 Displays Enhanced Anti-Inflammatory Properties in Microglial Cells.Journal of extracellular biology · 2026Article
- Temporal shifts in polygenic traits track major epidemics in Western Eurasia.bioRxiv : the preprint server for biology · 2026Article
- IL-11 acts as an alarmin-like pro-inflammatory mediator regulating mucosal responses during helminth infection.Mucosal immunology · 2026Article
- Host Serum Biomarker Signatures in Mycobacteriologically Cured Pulmonary Tuberculosis Patients with Persistent Lung Inflammation on 18F-FDG PET/CT.Diseases (Basel, Switzerland) · 2026Article
- Neurons differentially upregulate type 2 immune cytokines and interleukin-4 receptor subtypes during neuroinflammation.Acta neuropathologica communications · 2026Article
- Cell-Free DNA-Based Theranostics for Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Multistrain Probiotics Alleviate Diarrhea by Modulating Microbiome-Derived Metabolites and Serotonin Pathway.Probiotics and antimicrobial proteins · 2025Article
- G-CSF-Induced Emergency Granulopoiesis Modulates Neutrophil Effector Function in Mice.Stem cell reviews and reports · 2025Article
- A causal effects of neutrophil extracellular traps and its biomarkers on acute respiratory distress syndrome: a two-sample Mendelian randomization study.Scientific reports · 2025Article
- Systemic barrier dysfunction in type 2 inflammation diseases: perspective in the skin, airways, and gastrointestinal tract.Immunologic research · 2025Review
- Case Report: Rare Dupilumab-Associated Pulmonary and Extrapulmonary Tuberculosis.Infection and drug resistance · 2025Article
- Dose-response effects of multiple Ascaris suum exposures and their impact on lung protection during larval ascariasis.PLoS neglected tropical diseases · 2024Article
- Neutrophils in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2024Review
- NO Casting of NETs in Allergic Asthma.American journal of respiratory and critical care medicine · 2024Article
- Transcriptome Analysis of Human Dermal Cells Infected with Candida auris Identified Unique Pathogenesis/Defensive Mechanisms Particularly Ferroptosis.Mycopathologia · 2024Article
- The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors.Cancers · 2024Review
- Dynamic molecular network analysis of iPSC-Purkinje cells differentiation delineates roles of ISG15 in SCA1 at the earliest stage.Communications biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-4 (IL-4) receptor (IL-4R) signaling plays a pivotal role in type 2 immune responses. Type 2 immunity ensures several host-protective processes such as defense against helminth parasites and wound repair, however, type 2 immune responses also drive the pathogenesis of allergic diseases. Neutrophil granulocytes (neutrophils) have not traditionally been considered a part of type 2 immunity. While neutrophils might be beneficial in initiating a type 2 immune response, their involvement and activation is rather unwanted at later stages. This is evidenced by examples of type 2 immune responses where increased neutrophil responses are able to enhance immunity, however, at the cost of increased tissue damage. Recent studies have linked the type 2 cytokines IL-4 and IL-13 and their signaling via type I and type II IL-4Rs on neutrophils to inhibition of several neutrophil effector functions. This mechanism directly curtails neutrophil chemotaxis toward potent intermediary chemoattractants, inhibits the formation of neutrophil extracellular traps, and antagonizes the effects of granulocyte colony-stimulating factor on neutrophils. These effects are observed in both mouse and human neutrophils. Thus, we propose for type 2 immune responses that neutrophils are, as in other immune responses, the first non-resident cells to arrive at a site of inflammation or infection, thereby guiding and attracting other innate and adaptive immune cells; however, as soon as the type 2 cytokines IL-4 and IL-13 predominate, neutrophil recruitment, chemotaxis, and effector functions are rapidly shut off by IL-4/IL-13-mediated IL-4R signaling in neutrophils to prevent them from damaging healthy tissues. Insight into this neutrophil checkpoint pathway will help understand regulation of neutrophilic type 2 inflammation and guide the design of targeted therapeutic approaches for modulating neutrophils during inflammation and neutropenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.